SREN:SIXSwiss Re AG Analysis
Data as of 2026-03-10 - not real-time
CHF 127.95
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Swiss Re AG (SREN) is trading at CHF 127.95, which sits below its 20‑day SMA of 129.56 and well under the 200‑day SMA of 139.28, signalling short‑term weakness. The RSI of 47 is neutral, while the MACD histogram is negative and the signal line is bearish, suggesting downward momentum, even as trading volume is on the rise. The stock currently respects a support level around CHF 125.25 and faces resistance near CHF 138.70.
Fundamentally, the company appears undervalued with a trailing PE of 10.2 versus an industry average of 17.4, a price‑to‑book of 1.92 and a price‑to‑sales of 0.88. It delivers a robust dividend yield of 6.25% with a payout ratio of 45%, indicating dividend sustainability despite a 4.7% revenue decline and modest profit margins. The balance sheet shows a debt‑to‑equity of 33% and a low beta of 0.42, pointing to limited market volatility, though the 30‑day volatility of 22.7% and a max drawdown of 21% highlight historical price swings.
Market sentiment is currently in “Extreme Greed” territory (Fear‑Greed Index 78.9), yet sector‑specific risks—such as underwriting cycles, climate‑related losses, and regulatory scrutiny—temper optimism. Overall, the stock presents a mixed picture of valuation attractiveness and moderate risk, making a nuanced investment stance advisable.
Fundamentally, the company appears undervalued with a trailing PE of 10.2 versus an industry average of 17.4, a price‑to‑book of 1.92 and a price‑to‑sales of 0.88. It delivers a robust dividend yield of 6.25% with a payout ratio of 45%, indicating dividend sustainability despite a 4.7% revenue decline and modest profit margins. The balance sheet shows a debt‑to‑equity of 33% and a low beta of 0.42, pointing to limited market volatility, though the 30‑day volatility of 22.7% and a max drawdown of 21% highlight historical price swings.
Market sentiment is currently in “Extreme Greed” territory (Fear‑Greed Index 78.9), yet sector‑specific risks—such as underwriting cycles, climate‑related losses, and regulatory scrutiny—temper optimism. Overall, the stock presents a mixed picture of valuation attractiveness and moderate risk, making a nuanced investment stance advisable.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish MACD and price below 20‑day SMA
- Increasing volume indicating potential short‑term bounce
- High dividend yield providing downside cushion
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Undervalued relative to peers (low PE, low P/B)
- Sustainable dividend supporting total return
- Low beta and improving cash flow trends
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Stable, high dividend yield with moderate payout ratio
- Limited growth prospects due to revenue contraction
- Low market volatility and solid balance‑sheet metrics
Key Metrics & Analysis
Financial Health
Revenue Growth-4.70%
Profit Margin11.06%
P/E Ratio10.2
ROE19.44%
ROA3.14%
Debt/Equity33.17
P/B Ratio1.9
Industry P/E17.4
Technical Analysis
TrendNeutral
RSI47.2
SupportCHF 125.25
ResistanceCHF 138.70
MA 20CHF 129.56
MA 50CHF 127.82
MA 200CHF 139.28
MACDBearish
VolumeIncreasing
Fear & Greed Index78.89
Valuation
Target PriceCHF 129.89
Upside/Downside1.52%
GradeUndervalued
TypeValue
Dividend Yield6.25%
Risk Assessment
Beta0.42
Volatility22.75%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.